439 related articles for article (PubMed ID: 17591525)
1. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.
Al-Aly Z; Qazi RA; González EA; Zeringue A; Martin KJ
Am J Kidney Dis; 2007 Jul; 50(1):59-68. PubMed ID: 17591525
[TBL] [Abstract][Full Text] [Related]
2. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate?
Qunibi WY; Abdellatif A; Sankar S; Hamdan Z; Lin FY; Ingle J; Cadena A; Gelfond J; Kasinath B
Clin Nephrol; 2010 Apr; 73(4):276-85. PubMed ID: 20353735
[TBL] [Abstract][Full Text] [Related]
3. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
[TBL] [Abstract][Full Text] [Related]
5. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
Trakarnvanich T; Chalapipat O; Disthabanchong S; Kurathong S; Praditpornsilpa K; Stitchantrakul W; Chailurkit LO
J Med Assoc Thai; 2010 Aug; 93(8):885-91. PubMed ID: 20718162
[TBL] [Abstract][Full Text] [Related]
6. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
[TBL] [Abstract][Full Text] [Related]
7. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients.
Boudville NC; Hodsman AB
Nephrol Dial Transplant; 2006 Sep; 21(9):2621-4. PubMed ID: 16644777
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
9. Effects of Vitamin D
Batacchi Z; Robinson-Cohen C; Hoofnagle AN; Isakova T; Kestenbaum B; Martin KJ; Wolf MS; de Boer IH
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1498-1506. PubMed ID: 28768705
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
[TBL] [Abstract][Full Text] [Related]
11. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
12. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease.
DeVille J; Thorp ML; Tobin L; Gray E; Johnson ES; Smith DH
Nephrology (Carlton); 2006 Dec; 11(6):555-9. PubMed ID: 17199797
[TBL] [Abstract][Full Text] [Related]
13. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
[TBL] [Abstract][Full Text] [Related]
14. Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone.
Garcia-Lopes MG; Pillar R; Kamimura MA; Rocha LA; Canziani ME; Carvalho AB; Cuppari L
Ann Nutr Metab; 2012; 61(1):74-82. PubMed ID: 22889840
[TBL] [Abstract][Full Text] [Related]
15. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional analysis of abnormalities of mineral homeostasis, vitamin D and parathyroid hormone in a cohort of pre-dialysis patients. The chronic renal impairment in Birmingham (CRIB) study.
Zehnder D; Landray MJ; Wheeler DC; Fraser W; Blackwell L; Nuttall S; Hughes SV; Townend J; Ferro C; Baigent C; Hewison M
Nephron Clin Pract; 2007; 107(3):c109-16. PubMed ID: 17890873
[TBL] [Abstract][Full Text] [Related]
17. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
18. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
19. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5.
Gravesen E; Hofman-Bang J; Lewin E; Olgaard K
Scand J Clin Lab Invest; 2013 Mar; 73(2):107-16. PubMed ID: 23281842
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients.
Shah N; Bernardini J; Piraino B
Perit Dial Int; 2005; 25(4):362-6. PubMed ID: 16022093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
